Akari Therapeutics Plc (AKTX) insider trading.
In Q3 2026, insiders at Akari Therapeutics Plc reported 5 non-derivative transactions on 3 Forms 3, 4 and 5: 0 open-market purchases and 0 sales.
- Transactions
- 5
- Purchases (P)
- 0
- Sales (S)
- 0
- Net shares, P minus S
- 0
- Insiders
- 2
- Last filed
- 2026-08-19
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Patel Samir Rashmikant | Director, TenPercentOwner | 3 | 0 | 0 |
| Farag Kameel D. | Officer · Interim CFO | 2 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-17 | Farag Kameel D. | A (A) | 1,728 | $7.52 | 23,309 | Form 4 |
| 2026-07-16 | Farag Kameel D. | A (A) | 1,130 | $11.5 | 21,581 | Form 4 |
| 2026-07-07 | Patel Samir Rashmikant | M (A) | 1,209 | $8 | 76,976 | Form 4 |
| 2026-07-07 | Patel Samir Rashmikant | M (A) | 15,466 | $0 | 92,442 | Form 4 |
| 2026-07-07 | Patel Samir Rashmikant | M (A) | 5,799 | $0 | 98,241 | Form 4 |
Transaction codes in this quarter
Get AKTX insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1541157&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · AKTX company page · Akari Therapeutics Plc on SEC.gov
Questions
Are insiders buying or selling Akari Therapeutics Plc (AKTX)?
In Q3 2026, insiders at Akari Therapeutics Plc reported 5 non-derivative transactions on 3 Forms 3, 4 and 5: 0 open-market purchases and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Akari Therapeutics Plc insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/aktx.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.